Introduction
Evidence based medicine [EBM] at bedside, a key healthcare quality measure, refers to the compendium for delivering optimum clinical care by balancing benefit-harm-costs. EBM involves appraisal, interpretation and implementation with adoption of beneficial interventions and de-adoption of interventions with potential harm.
Our hypothesis from Niven et al [1] where the reversal of intervention effect was not associated with timely de-adoption, is that for a rapid change in clinical practice perceived cost [ 
Objectives
We explored the impact of reversal of intervention effect in septic shock trials on the adoption -de-adoption cycle of these three interventions; hypothesis being visible 'cost' influences EBM. Figure 1b] . Between the publications of Leuven-2 [5] and NICE-SUGAR [6] studies, the population average glucose values by quarter increased gradually from 5.7 to 7.6 mmol/L, over the study period. This was associated with reduction in hypoglycemia incidence [ Figure 1c] .
Conclusions
This descriptive analysis supports our hypothesis. Further analysis will identify key drivers for 'timely' EBM beyond SSC bundle compliance. 
